Directed share issue in Camurus AB (SE) — SEK 300 million

Carnegie acted as joint global co-ordinators in the directed new share issue of 2,000,000 shares at a subscription price of SEK 150 per share. Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. July 2020.